95 related articles for article (PubMed ID: 10607876)
1. Cardiovascular and renal effects of central administration of a mineralocorticoid receptor antagonist in conscious female rats.
Rahmouni K; Barthelmebs M; Grima M; Imbs JL; De Jong W
Eur J Pharmacol; 1999 Dec; 385(2-3):199-202. PubMed ID: 10607876
[TBL] [Abstract][Full Text] [Related]
2. Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension.
Rahmouni K; Sibug RM; De Kloet ER; Barthelmebs M; Grima M; Imbs JL; De Jong W
Eur J Pharmacol; 2002 Feb; 436(3):207-16. PubMed ID: 11858800
[TBL] [Abstract][Full Text] [Related]
3. Influence of sodium intake on the cardiovascular and renal effects of brain mineralocorticoid receptor blockade in normotensive rats.
Rahmouni K; Barthelmebs M; Grima M; Imbs JL; De Jong W
J Hypertens; 2002 Sep; 20(9):1829-34. PubMed ID: 12195126
[TBL] [Abstract][Full Text] [Related]
4. Brain mineralocorticoid receptor control of blood pressure and kidney function in normotensive rats.
Rahmouni K; Barthelmebs M; Grima M; Imbs JL; Wybren De Jong
Hypertension; 1999 May; 33(5):1201-6. PubMed ID: 10334812
[TBL] [Abstract][Full Text] [Related]
5. Involvement of brain mineralocorticoid receptor in salt-enhanced hypertension in spontaneously hypertensive rats.
Rahmouni K; Barthelmebs M; Grima M; Imbs JL; De Jong W
Hypertension; 2001 Oct; 38(4):902-6. PubMed ID: 11641306
[TBL] [Abstract][Full Text] [Related]
6. Central effects of mineralocorticoid antagonist RU-28318 on blood pressure of DOCA-salt hypertensive rats.
Van den Berg DT; de Kloet ER; de Jong W
Am J Physiol; 1994 Dec; 267(6 Pt 1):E927-33. PubMed ID: 7810636
[TBL] [Abstract][Full Text] [Related]
7. [Brain mineralocorticoid receptor and blood pressure control in the conscious normotensive rat].
Rahmouni K; Barthelmebs M; Imbs JL; De Jong W
Arch Mal Coeur Vaiss; 1998 Aug; 91(8):1009-12. PubMed ID: 9749155
[TBL] [Abstract][Full Text] [Related]
8. Mineralocorticoid antagonist inhibits stress-induced blood pressure response after repeated daily warming.
Van den Berg DT; de Jong W; de Kloet ER
Am J Physiol; 1994 Dec; 267(6 Pt 1):E921-6. PubMed ID: 7810635
[TBL] [Abstract][Full Text] [Related]
9. Intracerebroventricular administration of a glucocorticoid receptor antagonist enhances the cardiovascular responses to brief restraint stress.
Van Acker SA; Fluttert MF; Sibug RM; De Kloet ER
Eur J Pharmacol; 2001 Oct; 430(1):87-91. PubMed ID: 11698067
[TBL] [Abstract][Full Text] [Related]
10. Differential central effects of mineralocorticoid and glucocorticoid agonists and antagonists on blood pressure.
van den Berg DT; de Kloet ER; van Dijken HH; de Jong W
Endocrinology; 1990 Jan; 126(1):118-24. PubMed ID: 2293978
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats.
Nielsen FT; Jensen BL; Marcussen N; Skøtt O; Bie P
Nephrol Dial Transplant; 2008 Sep; 23(9):2777-83. PubMed ID: 18424460
[TBL] [Abstract][Full Text] [Related]
12. Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension.
Gómez-Sánchez EP; Fort CM; Gómez-Sánchez CE
Am J Physiol; 1990 Mar; 258(3 Pt 1):E482-4. PubMed ID: 2316642
[TBL] [Abstract][Full Text] [Related]
13. On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation.
Ratka A; Sutanto W; Bloemers M; de Kloet ER
Neuroendocrinology; 1989 Aug; 50(2):117-23. PubMed ID: 2550833
[TBL] [Abstract][Full Text] [Related]
14. Anxiolytic-like effects of selective mineralocorticoid and glucocorticoid antagonists on fear-enhanced behavior in the elevated plus-maze.
Korte SM; de Boer SF; de Kloet ER; Bohus B
Psychoneuroendocrinology; 1995; 20(4):385-94. PubMed ID: 8532822
[TBL] [Abstract][Full Text] [Related]
15. Role of brain corticosterone and aldosterone in central angiotensin II-induced hypertension.
Huang BS; White RA; Ahmad M; Leenen FH
Hypertension; 2013 Sep; 62(3):564-71. PubMed ID: 23856493
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid and glucocorticoid receptor antagonists in animal models of anxiety.
Korte SM; Korte-Bouws GA; Koob GF; De Kloet ER; Bohus B
Pharmacol Biochem Behav; 1996 May; 54(1):261-7. PubMed ID: 8728567
[TBL] [Abstract][Full Text] [Related]
17. Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension.
Gabor A; Leenen FH
Hypertension; 2013 May; 61(5):1083-90. PubMed ID: 23509081
[TBL] [Abstract][Full Text] [Related]
18. DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats.
Nariai T; Fujita K; Kawane K; Mori M; Nakayama R; Matsuda K; Katayama S; Fukuda N; Hori S; Iwata M; Hasegawa F; Suzuki K; Kato H
J Pharmacol Exp Ther; 2015 Jul; 354(1):2-9. PubMed ID: 25922341
[TBL] [Abstract][Full Text] [Related]
19. Central mineralocorticoid receptor antagonism blocks hypertension in Dahl S/JR rats.
Gomez-Sanchez EP; Fort C; Thwaites D
Am J Physiol; 1992 Jan; 262(1 Pt 1):E96-9. PubMed ID: 1310219
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats.
Kawarazaki H; Ando K; Nagae A; Fujita M; Matsui H; Fujita T
Nephrol Dial Transplant; 2010 Sep; 25(9):2879-89. PubMed ID: 20466668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
